Dermatitis

LATEST NEWS

Factors Associated With More Severe AD in Children

By

Brandon May

Factors associated with severe atopic dermatitis in later childhood and self-reported triggers are reported.

Patients With Hand Eczema Report High Levels of Stress

By

Brandon May

The clinic-etiological factors of patients with hand eczema were assessed.

Upadacitinib Bests Dupilumab in Atopic Dermatitis Trial

By

Brian Park, PharmD

The randomized, double-blind, double-dummy, active-controlled Heads Up study included 692 patients aged 18 to 75 years with moderate to severe atopic dermatitis who are candidates for systemic therapy.

Atopic Dermatitis Linked to Increased Risk for Autoimmune Disease

By

Brandon May

The association of atopic dermatitis and autoimmune disease was investigated.

Weak Evidence of Causal Relationship of Vitamin D and Atopic Dermatitis

By

Colby Stong

The causal effect of genetically predicted vitamin D levels on atopic dermatitis risk was investigated.

Increased Conjunctivitis Risk Observed in Patients Initiated Dupilumab for Atopic Dermatitis

By

Emily Pond

The 6-month risk for conjunctivitis in patients with atopic dermatitis treated with dupilumab was evaluated.

Atopic Dermatitis Does Not Appear to Affect COVID-19 Severity

By

Chen Fang, PharmD, RPh

Investigators evaluated the relationship between atopic dermatitis and frequency of severity markers in patients hospitalized with COVID-19.

Abrocitinib Associated With Less Flare in Atopic Dermatitis Trial

By

Diana Ernst, RPh

The JADE REGIMEN trial was a responder-enriched, placebo-controlled withdrawal study that included a 12-week open-label run-in period.

EASI 50, SCORAD 35, and O-SCORAD 35 May Be Most Meaningful MICs for Atopic Dermatitis

By

Colby Stong

The minimal important changes of percentage and absolute improvement of EASI and SCORAD scores in adults and children with AD was determined.

Topical Live Biotherapeutic Gets Fast Track Status for Atopic Dermatitis

By

Brian Park, PharmD

FB-401 is a topically applied live biotherapeutic that consists of 3 therapeutic strains of commensal Roseomonas mucosa.